Dr. Schlaepfer’s lab focusses on understanding how cancer cells use fats for growth and resistance to therapy. Her current project funded by the American Cancer Society, focuses on the role of the CPT1A gene and its association with the androgen receptor. CPT1A functions as a gatekeeper, mediating the entry of lipid into the mitochondria for oxidation and growth. The androgen receptor mediates the effects of the male hormone androgen, and promotes prostate cancer growth.
Prostate cancer metastasis are generally treated with androgen ablation, but most patients relapse to an incurable castration resistant state that is incurable. Dr Schlaepfer has found that blocking the CPT1A gene activity makes the cells more sensitive to the drugs that target the androgen receptor, offering new avenues of therapy for incurable prostate cancer.
K01CA168934 - Targeting Lipid Oxidation for Prostate Cancer Imaging and Therapy Pilot Project Award - Enhancement of FDG-PET with metabolic inhibitors Pilot Project Junior Faculty Award - Pilot study to enhance 18F-FDG-PET imaging of human prostate cancer with ranolazine
American Cancer Society RSG; CPT1A-mediated fat oxidation as a therapeutic target in prostate cancer.